{'fraction_non_alphanumeric': 0.03109452736318408, 'fraction_numerical': 0.017412935323383085, 'mean_word_length': 5.24031007751938, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Expression of mage genes by non‐small‐cell lung carcinomas

Human gene MAGE‐1 codes for an antigen that is recognized on melanoma cells by autologous cytolytic T lymphocytes (CTL). This antigen is potentially useful as a target for cancer immunotherapy because gene MAGE‐1 is not expressed in any normal tissues except the testis. We tested 46 surgical samples of non‐small‐cell lung carcinomas and observed MAGE‐1 expression in 16 of them (35%). Genes MAGE‐2 and 3, which are closely related to MAGE‐1, were expressed by a similar proportion of these tumors. Some small‐cell lung tumors also express MAGE genes. The proportion of tumors expressing MAGE‐1 suggests that lung tumor patients may constitute the largest group of patients potentially eligible for pilot studies involving MAGE‐1 immunization.